Abingdon HealthABDXF +8.93%49 FCF Margin % is -30.96% as of Dec. 2025. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.21 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Abingdon Health ranks worse than 71.08% on this metric.
The historical rank and industry rank for Abingdon Health's FCF Margin % or its related term are showing as below:
ABDXF'
s FCF Margin % Range Over the Past 10 Years
Min: -299.79 Med: -41.86 Max: 18.69
Current: -27.54
During the past 8 years, the highest FCF Margin % of Abingdon Health was 18.69%. The lowest was -299.79%. And the median was -41.86%.
ABDXF's FCF Margin % is ranked worse than 71.08% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs ABDXF: -27.54
Abingdon Health FCF Margin % Related Terms
Abingdon Health FCF Margin % Historical Data
* Premium members only.
The historical data trend for Abingdon Health's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Abingdon Health's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Abingdon Health's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abingdon Health (ABDXF) has a FCF Margin % of -30.96% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Abingdon Health and its competitors. According to the industry distribution chart, Abingdon Health ranks #145 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 71.1%.
Is Abingdon Health's FCF Margin % too high?
Abingdon Health's current FCF Margin % is -30.96%. Based on the distribution chart, Abingdon Health ranks #145 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #145 out of 204 companies for FCF Margin %. This places Abingdon Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Abingdon Health and its competitors. Abingdon Health's current FCF Margin % is -30.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.21, compared to a current price of $0.15 — trading 27.4% below its estimated fair value. The current FCF Margin % is -30.96%. Abingdon Health's overall GF Score™ is 49/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current FCF Margin % is -30.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abingdon Health (ABDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued.
The current stock price of $0.15 is trading 27.4% below its estimated GF Value™ of $0.21.
GuruFocus considers Abingdon Health to be Modestly Undervalued.
Key valuation signals for ABDXF:
FCF Margin %: -30.96%
GF Value™: $0.21 vs. price of $0.15 (27.4% below fair value)
No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score
Get the complete analysis for ABDXF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABDXF has been successfully added to your 
